Recursion Pharmaceuticals (NasdaqGS:RXRX) reported a 10% decline in its share price last week as it announced first-quarter 2025 results with an increased net loss despite rising sales and revenue.

CAVA Group (NYSE:CAVA) recently announced an increase in sales and net income for the first quarter of 2025, maintaining its earnings guidance for the year. Despite this positive performance, the ...

RTX Corporation's is being resilient amid defense/travel trends, managing tariff impacts with US-based expansions, while ...

Foreign Portfolio Investors sold shares worth ₹4,784.32 crore between May 19-23, reducing net inflows for May to ₹13,835 ...

Honest Complaints, Real User Experiences, and How This 2025 LED Toenail Device Compares to Traditional Fungus ...